Anti-wart

Bufo Rana, Buxus Sempervirens, Juglans Regia, Nitricum Acidum, Oleander, Stannum Metallicum, Sulphur, Taxus Baccata, Thuja Occidentalis, Vanadium Metallicum

Seroyal Usa
Human Otc Drug
NDC 62106-1238

Anti-wart also known as Bufo Rana, Buxus Sempervirens, Juglans Regia, Nitricum Acidum, Oleander, Stannum Metallicum, Sulphur, Taxus Baccata, Thuja Occidentalis, Vanadium Metallicum is a human otc drug labeled by 'Seroyal Usa'. National Drug Code (NDC) number for Anti-wart is 62106-1238. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Anti-wart drug includes Bufo Bufo Cutaneous Gland - 12 [hp_X]/20mL Buxus Sempervirens Leafy Twig - 6 [hp_X]/20mL English Walnut - 2 [hp_X]/20mL Nerium Oleander Leaf - 6 [hp_X]/20mL Nitric Acid - 10 [hp_X]/20mL Sulfur - 10 [hp_X]/20mL Taxus Baccata Whole - 6 [hp_X]/20mL Thuja Occidentalis Leafy Twig - 8 [hp_X]/20mL Tin - 10 [hp_X]/20mL Vanadium - 10 [hp_X]/20mL . The currest status of Anti-wart drug is Active.

Drug Information:

Drug NDC:	62106-1238
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name:	Anti-wart
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type:	Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name:	Bufo Rana, Buxus Sempervirens, Juglans Regia, Nitricum Acidum, Oleander, Stannum Metallicum, Sulphur, Taxus Baccata, Thuja Occidentalis, Vanadium Metallicum
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name:	Seroyal Usa
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form:	Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status:	Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:	BUFO BUFO CUTANEOUS GLAND - 12 [hp_X]/20mL BUXUS SEMPERVIRENS LEAFY TWIG - 6 [hp_X]/20mL ENGLISH WALNUT - 2 [hp_X]/20mL NERIUM OLEANDER LEAF - 6 [hp_X]/20mL NITRIC ACID - 10 [hp_X]/20mL SULFUR - 10 [hp_X]/20mL TAXUS BACCATA WHOLE - 6 [hp_X]/20mL THUJA OCCIDENTALIS LEAFY TWIG - 8 [hp_X]/20mL TIN - 10 [hp_X]/20mL VANADIUM - 10 [hp_X]/20mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:	ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Marketing Category:	UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date:	03 Apr, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date:	08 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date:	31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Manufacturer Name:	Seroyal USA
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:	Yes
Whether or not the drug has been repackaged for distribution.
NUI:	N0000185371 N0000175629 N0000184306 M0000728 M0006342 N0000185019
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:	Q59QU6N72Q L479H0RS38 1V3SHR7QB7 7KV510R6H6 411VRN1TV4 70FD1KFU70 T0311VH21D 1NT28V9397 387GMG9FH5 00J9J9XKDE
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:	Non-Standardized Food Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:	Increased Histamine Release [PE] Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:	Allergens [CS] Dietary Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:	Allergens [CS] Cell-mediated Immunity [PE] Dietary Proteins [CS] Increased Histamine Release [PE] Non-Standardized Food Allergenic Extract [EPC] Nut Proteins [EXT]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDC	Description	Marketing Start Date	Marketing End Date	Sample Available
62106-1238-8	1 BOTTLE, GLASS in 1 CARTON (62106-1238-8) / 20 mL in 1 BOTTLE, GLASS	03 Apr, 2017	N/A	No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Other medicines with the same generic name

Anti-wart

Bufo Rana & more..

Liquid
Seroyal USA
NDC: 62106-1238

Purpose:

Uses for the temporary relief of symptoms associated with skin warts.

Product Elements:

Anti-wart bufo rana, buxus sempervirens, juglans regia, nitricum acidum, oleander, stannum metallicum, sulphur, taxus baccata, thuja occidentalis, vanadium metallicum tin tin english walnut english walnut nerium oleander leaf nerium oleander leaf alcohol water lactose bufo bufo cutaneous gland bufo bufo cutaneous gland nitric acid nitric acid sulfur sulfur thuja occidentalis leafy twig thuja occidentalis leafy twig vanadium vanadium buxus sempervirens leafy twig buxus sempervirens leafy twig taxus baccata whole taxus baccata whole

Indications and Usage:

Uses for the temporary relief of symptoms associated with skin warts. directions to be taken ten minutes away from food. invert bottle and shake lightly allowing drops to fall directly under the tongue or into Â¼ oz of water. hold contents for about 20 seconds and swallow. to promote drop flow, invert bottle and shake before each use. adults and adolescents (12 years and older) take 10 drops two times daily, in the morning and evening, or as recommended by your healthcare practitioner. children (under 12 years) take under the direction of your healthcare practitioner.

Warnings:

Warnings stop use and ask a doctor if symptoms persist or worsen. if pregnant or breastfeeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away.

Dosage and Administration:

Directions to be taken ten minutes away from food. invert bottle and shake lightly allowing drops to fall directly under the tongue or into Â¼ oz of water. hold contents for about 20 seconds and swallow. to promote drop flow, invert bottle and shake before each use. adults and adolescents (12 years and older) take 10 drops two times daily, in the morning and evening, or as recommended by your healthcare practitioner. children (under 12 years) take under the direction of your healthcare practitioner.

Package Label Principal Display Panel:

Ndc 62106-1238-8 unda plex anti-wart homeopathic preparation for the temporary relief of symptoms associated with skin warts. contains 30% alcohol 0.7 fl oz (20 ml) 62106-1238-8

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.